Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Life Technologies Enters into an Exclusive License and Supply Agreement for Dynabead

Published: Thursday, August 01, 2013
Last Updated: Thursday, August 01, 2013
Bookmark and Share
Life Technologies has signed a long-term supply and exclusive licensing agreement with Novartis for immunotherapeutics involving T cells modified to express chimeric antigen receptors for the treatment of cancer.

Life Technologies will provide the company's proprietary technology, Dynabeads® CD3/CD28 CTS™, which possess unique biological properties suited to production of active, therapeutically relevant immune system cells.

The agreement includes rights to use Life Technologies' intellectual property to perform the resulting therapy, and is exclusive for use in the field of chimeric antigen receptors for the treatment of cancer.

"The collaboration with Novartis highlights the distinct capabilities that Life Technologies can provide in the therapeutic realm," said Greg Lucier, chairman and chief executive officer of Life Technologies. "Taken with our previous announcements of companion diagnostic collaborations, the current agreement demonstrates how Life is uniquely positioned to facilitate drug development through alliances with pharma."

Chimeric antigen receptor T cell based immunotherapy constitutes a novel, individualized method of combating cancers. Novartis is working to commercialize technology developed at the University of Pennsylvania that has demonstrated startling efficacy in research studies. In two 2011 publications1,2, University of Pennsylvania researchers described application of immunotherapy in three patients, all of whom experienced durable complete or partial remission of their cancers within three to four weeks of treatment. A 2013 publication in the New England Journal of Medicinedescribed complete responses with one ongoing in two children with leukemia3.

The personalized therapy consists of removing blood cells from cancer patients; isolating  and activating T cells; genetically modifying the T cells thereby programming those cells to recognize and attack cancer cells; expanding  the T cells; and, lastly, introducing those cells back into the body so the patient's immune system can take over. Under the terms of the current agreement, Life Technologies' Dynabeads® CD3/CD28 CTS™, will be used to isolate, activate and expand the T cells.

"Dynabeads ® CD3/CD28 CTS™ have unique properties that are ideal for producing a robust immunotherapeutic," said Oystein Aamellem, head of Cellular Medicine at Life Technologies. "Not only do the beads assure that T cells are separated from any unwanted cells, it also triggers the T cells to reproduce in a natural and controlled manner, ensuring a therapeutically relevant population is transferred back into the patient."

"The current agreement with Novartis represents a significant step in the growth of Life Technologies from a research tools provider to a leading medical device company," said Lucier. "We're very excited about the opportunity to work with Novartis to deliver novel therapeutics to fill a critical need in cancer care."

1. Chimeric Antigen Receptor—Modified T Cells in Chronic Lymphoid Leukemia. Porter, David L., et. al.; N Engl J Med 2011; 365:725-733.

2. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia. Kalos, Michael, et. al.; Sci Transl Med 10 August 2011: Vol. 3, Issue 95, p. 95.

3. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. Grupp, Stephan A., et al.; N Engl J Med 2013; 368;1509-1518.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Thermo Acquisition Approved by Life Technologies Stockholders
Company announced that its stockholders voted to adopt the previously announced merger agreement.
Thursday, August 22, 2013
Life Technologies Establishes International Influenza Network
Scientists at leading public health agencies and research institutes collaborate to develop faster, more reliable flu subtyping methods.
Friday, February 01, 2013
Life Technologies Signs Collaborative Agreement with Structural Genomics Consortium
Pioneering joint venture releases 58 of 200 planned, highly-specific recombinant antibodies for epigenetic studies.
Thursday, July 19, 2012
Life Technologies to Accelerate Development of Ion Torrent Semiconductor Technology
Company to accelerate technology for a broad set of proteomic and antibody-based applications after passing internal Life Technologies R&D milestones.
Thursday, July 12, 2012
Scientific News
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
New Strategy for Combating Adenoviruses
Using an animal model they developed, Saint Louis University and Utah State university researchers have identified a strategy that could keep a common group of viruses called adenoviruses from replicating and causing sickness in humans.
Major Advance Toward More Effective, Long-Lasting Flu Vaccine
Collaboration shows vaccine candidate can produce powerful ‘broadly neutralizing antibodies’ in animal models.
Immune System: Help for Killer Cells
A study from the University of Bonn may show the way to more effective vaccines.
Protein Found to Control Inflammatory Response
A new Northwestern Medicine study shows that a protein called POP1 prevents severe inflammation and, potentially, diseases caused by excessive inflammatory responses.
A Leap Forward in Vaccinating Against HIV
A team of scientists has developed an experimental vaccine candidate that successfully stimulates the immune system activity in animal models necessary to stop HIV infection.
MRI Scanners Can Steer Therapeutics to Specific Target Sites
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!